Researchers break decades-old bottleneck in chemotherapy drug manufacturing

 Researchers break decades-old bottleneck in chemotherapy drug manufacturing  An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent. The study identifies and resolves molecular “bottlenecks” that have limited the natural production of this drug for over 50 years.  Doxorubicin is a chemotherapy drug…

Continue Reading

Lurie Autism Institute Announces Dr. Huda Zoghbi as the Inaugural Recipient of the Nancy Lurie Marks Prize for Autism Research

Mar 13 – The Lurie Autism Institute, a joint initiative of Children’s Hospital of Philadelphia (CHOP) and Penn Medicine created to drive discovery, develop new treatments, and improve the lives of individuals and families affected by autism, is proud to announce that geneticist Huda Y. Zoghbi, MD, has been selected as the inaugural recipient of…

Continue Reading

Diabetes, Hypertension Major Risk Factors for Kidney Disease, Say CARE Doctors

Hyderabad, Mar 12: Marking World Kidney Day 2026, doctors at CARE Hospitals, Hyderabad have raised concern over the growing burden of kidney disease in India and stressed the importance of early detection, regular screening and lifestyle changes to prevent serious kidney complications.   Kidneys play a crucial role in filtering waste from the blood, maintaining fluid balance, regulating blood pressure and supporting…

Continue Reading

kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics

Paris, 9 March, 2026 – kyron.bio, a biotechnology company pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier, an international pharmaceutical group governed by a Foundation. Under the terms of the agreement, kyron.bio will use its technology to glycoengineer an antibody selected by Servier, who will…

Continue Reading

kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics

Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas Paris, Mar 09 – kyron.bio, a biotechnology company pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier, an international pharmaceutical group governed by a Foundation. Under…

Continue Reading